MOTS-c peptide dosage, as it appears in the research literature

Before the details

Everything about MOTS-c peptide dosage here comes from animal studies, and none of it is a human instruction. Researchers gave mice MOTS-c by injection into the abdominal cavity, at doses scaled to body weight — anywhere from a small daily dose to a much larger one, over weeks. There is no measured human half-life, no validated human dose, and no approved formulation. This page describes what was given to which animals by which route, so you can read the numbers in context, not follow them.

MOTS-c Dosage in the Research Literature

All published in-vivo dosing comes from rodents. The 2015 founding metabolic study used approximately 0.5 mg/kg/day intraperitoneally for chronic treatment (about 8 weeks) and 5 mg/kg/day intraperitoneally for a shorter acute protocol (7 days) ^[1]. The 2021 aged-mouse physical-capacity studies used 15 mg/kg/day, or 15 mg/kg three times weekly, intraperitoneally ^[2]. Bone studies have used 5 mg/kg/day intraperitoneally for 12 weeks ^[4].

Three things follow from reading those figures together. First, the dose range is wide — a thirtyfold spread from the 0.5 mg/kg chronic metabolic protocol to the 15 mg/kg performance protocol — because the studies were optimizing for different endpoints, metabolic homeostasis in one case and physical capacity in another ^[1][2]. Second, the frequency was matched to the endpoint, not to a clock: chronic metabolic and bone studies dosed daily over weeks, while the exercise work used both daily and thrice-weekly schedules ^[1][2][4]. Third, all of it is milligrams per kilogram — a body-weight-scaled laboratory figure, not a fixed amount.

These are doses administered to mice, scaled to the animal's body weight and expressed per kilogram. They are not human doses and cannot be converted into one — there is no human dose-response study to calibrate against, and allometric scaling from a mouse is not a validated substitute for a measured human dose ^[12]. This site does not provide a human dosing schedule.

Routes Studied: Intraperitoneal and Subcutaneous Injection

The dominant route in the literature is intraperitoneal (IP) injection — directly into the abdominal cavity — which is standard for rodent metabolic work and accounts for the figures above ^[1][2]. Subcutaneous injection appears in some research contexts, and cell-culture (in-vitro) work uses direct application ^[3][4]. Because native MOTS-c is a small unmodified peptide expected to be short-lived, some groups have engineered cell-penetrating analogues to improve delivery in specific models ^[4].

How often do you inject MOTS-c?

No human dosing schedule is validated. Rodent studies used daily or thrice-weekly intraperitoneal injection ^[1][2], and those frequencies were chosen for mouse experiments — they cannot be extrapolated to humans, and this digest does not recommend any human schedule.

Where is best to inject MOTS-c?

Rodent research used intraperitoneal injection — into the abdominal cavity — which is a laboratory technique, not a human practice ^[1][2]. There is no validated human injection-site guidance, and this digest does not provide administration instructions.

Can I inject MOTS-c every day?

Daily dosing was used in some rodent studies (for example, ~0.5 mg/kg/day in the 2015 metabolic work) ^[1], but no human regimen is validated and this digest does not recommend any human schedule ^[12].

How long should you take MOTS-c?

Rodent studies ran from roughly one week (acute protocols) to twelve weeks (chronic metabolic and bone endpoints) depending on what was being measured ^[1][4]. No human duration has been established, so there is no evidence-based answer for people ^[12].

MOTS-c Half-Life: No Validated Human Pharmacokinetics

There is no published, measured human pharmacokinetic half-life for MOTS-c ^[12]. As a small, unmodified peptide, native MOTS-c is expected to be short-lived in circulation, which is consistent with why published in-vivo work relies on repeated daily or thrice-weekly dosing rather than a measured human t1/2 ^[12]. Cell-penetrating analogues have been engineered specifically to improve delivery and exposure in research settings ^[4].

What is documented in humans is the body's own peptide, not an administered one. Circulating MOTS-c is measurable in plasma, shifts with exercise and metabolic state, and was independently associated with a mortality and cardiovascular endpoint in a 2024 hemodialysis cohort ^[4][8][13]. Those are endogenous-level measurements — they describe how much MOTS-c a person already makes, not how an injected dose behaves over time. A biomarker concentration is not a pharmacokinetic curve.

The practical consequence: without a validated half-life, bioavailability, or dose-response in humans, the rodent dosing figures above cannot be translated into a human interval or dose ^[12]. The gap is not a detail awaiting a footnote — it is the reason every dosing number on this page stays attached to the species and study it came from.

Reported Safety Signals and Unknowns

No completed human safety trial has characterized side effects for exogenous MOTS-c ^[12]. The animal studies above did not report the peptide as overtly toxic at the doses used, but rodent tolerability is not a human safety profile. The larger issue is structural: MOTS-c is sold only as a research chemical, and product purity, identity, and sterility are not regulated as pharmaceuticals and vary by supplier ^[12].

That combination — no human safety data, no validated PK, and unregulated material quality — is the honest summary of the safety picture. Anti-doping prohibition is a separate consideration covered on MOTS-c legal status and 503A access.

Stability and form

MOTS-c is supplied as a lyophilized (freeze-dried) powder for research; reconstitution and storage conditions are vendor- and study-specific, and no standardized human formulation exists ^[4].